SCHEMBL932027

SCHEMBL932027

NC(=O)N1C=CC=NC1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL933127 0.98
SCHEMBL28858341 0.96
Bicarbonate SCHEMBL28210330 0.92
SCHEMBL27674320 0.82
SCHEMBL933257 0.80
SCHEMBL27971657 0.80 TSHR (0.44)
SCHEMBL34471209 0.79
SCHEMBL4436164 0.78
SCHEMBL18281302 0.78
Acetic Acid SCHEMBL27989984 0.77

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 561 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4676488-A1 TREATMENT OF PARKINSON'S DISEASE IN A PATIENT USING A GLUCOCEREBROSIDASE ACTIVATOR Bial-R&D Investments, S.A. (PT) 2026-01-14 EP claimed
CN-120202200-A Oxo-isoindolinyl substituted tetrahydropyrimidinedione-based compounds and applications thereof 标新生物医药科技(上海)有限公司 2025-06-24 CN claimed
US-20240425510-A1 PROCESS FOR THE PREPARATION OF ZANUBRUTINIB OLON S.P.A. (IT) 2024-12-26 US claimed
WO-2024191312-A1 TREATMENT OF PARKINSON'S DISEASE IN A PATIENT USING A GLUCOCEREBROSIDASE ACTIVATOR BIAL – R&D Investments, S.A. (PT) 2024-09-19 WO claimed
EP-4416149-A1 PROCESS FOR THE PREPARATION OF ZANUBRUTINIB OLON S.p.A. (IT) 2024-08-21 EP claimed
EP-4247382-A1 METHODS OF TREATING SYSTEMIC LUPUS ERYTHEMATOSUS USING BTK INHIBITORS BeiGene Switzerland GmbH (CH) 2023-09-27 EP claimed
WO-2023062504-A1 PROCESS FOR THE PREPARATION OF ZANUBRUTINIB OLON S.P.A. (IT) 2023-04-20 WO claimed
WO-2023284703-A1 PROTEIN DEGRADATION COMPOUND DESIGNED ON THE BASIS OF BRUTON'S TYROSINE KINASE LIGAND AND APPLICATION THEREOF 标新生物医药科技(上海)有限公司 2023-01-19 WO claimed
CN-115417874-A Radioisotope carbon-14 labeled zebrafenib and preparation method thereof 浙江爱索拓标记医药科技有限公司 2022-12-02 CN claimed
US-20220306588-A1 BEZIMIDAZOLE DERIVATIVES AS ADENOSINE RECEPTOR ANTAGONISTS MERCK PATENT GMBH (DE) 2022-09-29 US claimed
CN-1826345-A Imidazo-pyrimidines and triazolo-pyrimidines: benzodiazepine receptor ligands NEUROGEN CORP A CORP OF THE ST (US) 2006-08-30 CN claimed
EP-1689752-A1 PYRAZOLOPYRIMIDINES Pfizer Limited (GB) 2006-08-16 EP claimed
WO-2005123738-A1 PYRRAZOLO-PYRIMIDINE DERIVATIVES F.HOFFMANN-LA ROCHE AG (CH) 2005-12-29 WO claimed
EP-1572113-A2 CALCIUM RECEPTOR MODULATING COMPOUND AND USE THEREOF Takeda Pharmaceutical Company Limited (JP) 2005-09-14 EP claimed
WO-2005049617-A1 PYRAZOLOPYRIMIDINES PFIZER LIMITED (GB) 2005-06-02 WO claimed
CN-1496262-A Triazolo [4, 5-d ] pyrimidine derivatives and their use as purinergic receptor antagonists О 2004-05-12 CN claimed
WO-2004019933-A1 METHOD OF PREVENTING OR TREATING ATHEROSCLEROSIS OR RESTENOSIS PHARMACIA & UPJOHN COMPANY (US) 2004-03-11 WO claimed
WO-2004017908-A2 CALCIUM RECEPTOR MODULATING COMPOUND AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2004-03-04 WO claimed
CN-1027263-C Process for preparing pyridopyrimidine derivatives CHINOIN CYOGYSZER ES VEGYSEZET (HU) 1995-01-04 CN claimed
CN-1036762-A Pyridopyrimidine derivatives contains the pharmaceutical composition and the method for making thereof of this derivative CHINOIN GYOGYSZER ES VEGYESZET (HU) 1989-11-01 CN claimed